Skip to contentH
Halozyme Therapeutics, Inc.
H
HALOHalozyme Therapeutics, Inc. Q3 2022 · 10-Q
Revenue$208.98M$208.98M+80.4% vs Q3 2021 Net Income$61.63M$61.63M−71.5% vs Q3 2021 EPS Diluted$0.44$0.44−70.3% vs Q3 2021 Operating Income$83,292,000+10.2% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$68,627,000−43.4% Margins · derivedOperating margin39.9%−25.4 pt vs Q3 2021
Net margin29.5%
ended Sep 30, 2022 · filed Nov 8, 2022 · 39 d after period end